Avalo Therapeutics (FRA:C6K0) Cyclically Adjusted PS Ratio: (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C6K0 Avalo Therapeutics Inc FRA:C6K0
42 GF Score
Price €16.66
GF Value €0.17
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Avalo Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avalo Therapeutics  (FRA:C6K0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Avalo Therapeutics Cyclically Adjusted PS Ratio Related Terms


Avalo Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Cyclically Adjusted PS Ratio Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.01 0.01 0.02

Avalo Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.02 0.00 0.00

FRA:C6K0 vs MRVI, LBRX, JANX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Avalo Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Cyclically Adjusted PS Ratio falls into.


FRA:C6K0
42GF Score
Avalo Therapeutics Inc FRA:C6K0
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Avalo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Avalo Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Avalo Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 95.333 241.428 131.868
201612 57.333 241.432 79.304
201703 89.750 243.801 122.937
201706 28.200 244.955 38.446
201709 1,750.583 246.819 2,368.581
201712 171.636 246.524 232.505
201803 330.545 249.554 442.334
201806 372.364 251.989 493.481
201809 291.000 252.439 384.964
201812 -396.429 251.233 -526.954
201903 152.000 254.202 199.686
201906 82.133 256.143 107.083
201909 133.267 256.759 173.333
201912 34.867 256.974 45.312
202003 131.158 258.115 169.694
202006 54.000 257.797 69.952
202009 36.269 260.280 46.535
202012 47.346 260.474 60.702
202103 12.806 264.877 16.146
202106 84.394 271.696 103.732
202109 32.800 274.310 39.932
202112 4.217 278.802 5.051
202203 27.308 287.504 31.720
202206 25.051 296.311 28.233
202209 387.128 296.808 435.575
202212 21.692 296.797 24.408
202303 9.061 301.836 10.025
202306 10.224 305.109 11.191
202309 1.133 307.789 1.229
202312 0.653 306.746 0.711
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.021 315.301 0.022
202412 0.017 315.605 0.018
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.003 324.054 0.003
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Avalo Therapeutics (FRA:C6K0) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of €16.66 is trading 9700% above its estimated GF Value™ of €0.17. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:C6K0:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.17 vs. price of €16.66 (9700% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the FRA:C6K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges AVTX:USAC6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
42GF Score

Get the complete analysis for FRA:C6K0

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.66
Price
€0.17
GF Value